MarketPeel
Insider Trading Intelligence
AB

Aoife Brennan

XLO
DIRECTOR · XILIO THERAPEUTICS, INC. · CIK 0001714563
FILING MIX · LIFETIME64%/36%
BUYS
7
SELLS
4
TOTAL VALUE
$432.1K
COMPANIES
2
ACTIVE SINCE
Jun 2024
HOLDINGS NOW
92,731
AVG SELL PX
$8.39
TRADE KIND
SHOWING 11 / 11
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Aoife Brennan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%+1.61%+0.46%+1.16%+1.16%
14d1+0.00%+14.52%+1.13%+13.39%+13.39%
30d1+0.00%+22.58%+2.69%+19.89%+19.89%
60d1+0.00%+79.84%+4.40%+75.44%+75.44%
90d1+0.00%+60.48%+7.42%+53.07%+53.07%
180d1+0.00%+297.58%+11.73%+285.85%+285.85%
1y1+0.00%+954.84%+19.93%+934.91%+934.91%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
XLO · 5,000 shares · as of Jun 11, 2026
012,50025,00037,50050,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 7 buys / 4 sellsCOVERAGE · 9 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CLYM
CLIMB BIO, INC.
SALE10b5-1
10b5-1 plan
30,902$13.17$407.0K87,731Jun 29, 2026Jun 30, 2026View →
CLYM
CLIMB BIO, INC.
PURCHASE
President and CEO
68,750118,633Jun 27, 2026Jun 30, 2026View →
CLYM
CLIMB BIO, INC.
SALE
President and CEO
68,750137,500Jun 27, 2026Jun 30, 2026View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,0005,000Jun 11, 2026Jun 12, 2026View →
CLYM
CLIMB BIO, INC.
PURCHASEGRANT
Stock grant
700,000700,000Jan 6, 2026Jan 8, 2026View →
CLYM
CLIMB BIO, INC.
SALE10b5-1
10b5-1 plan
20,618$1.22$25.2K48,132Jun 30, 2025Jul 1, 2025View →
CLYM
CLIMB BIO, INC.
SALE
President and CEO
68,750206,250Jun 27, 2025Jul 1, 2025View →
CLYM
CLIMB BIO, INC.
PURCHASE
President and CEO
68,75068,750Jun 27, 2025Jul 1, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
31,00031,000Jun 11, 2025Jun 12, 2025View →
CLYM
CLIMB BIO, INC.
PURCHASEGRANT
Stock grant
1,150,0001,150,000Jan 13, 2025Jan 15, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,00050,000Jun 13, 2024Jun 17, 2024View →
Other insiders · XLO
Loading peer insiders…
About this filer
CIK 0001714563
ROLE
Director
PRIMARY
XLO
COMPANIES
2
ACTIVE SINCE
Jun 2024
MARKETPEEL · /INSIDER/0001714563DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback